Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at 2026 ASCO Annual Meeting show ODM-212 was well tolerated, with proteinuria being the most common…
BMO Beats Quarterly Earnings Again, And Remains A Strong Dividend Idea Among Banks (BMO)
Bank of Montreal (BMO) remains a buy, supported by robust segment growth, dividend strength, and a conservative balance sheet, despite a rich valuation. BMO's Q2 saw YoY revenue growth across all business lines, with wealth and capital markets as…
Stock Split Watch: Is Eli Lilly Next?
Eli Lilly (LLY 1.93%) may not immediately come to mind when you think of growth stocks. Instead, you might think of technology or even consumer-oriented players. But Lilly actually has shown itself to be a top growth player in recent quarters, and…
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
The big news in the GLP-1 weight loss drug space right now is the introduction of pills. That seems to have broadened the appeal of GLP-1s, as many consumers simply don't like to take shots. Eli Lilly (LLY 1.87%) just introduced its own pill…
Thriving in the Age of Overwhelm
How can you separate market signal from media noise when headlines are designed to hijack your attention? In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributor Rachel Warren talks with Fred Marshall, author of Thrive: The…
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date…
Intech Investment Management LLC Has $12.49 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA
Intech Investment Management LLC lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 9.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange…
Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Moderna, Inc. (MRNA) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDT Stéphane Bancel – CEO & Director Courtney Breen – Bernstein Institutional Services LLC, Research Division Bernstein…
Pluralistic: Carneyism without Carney (30 May 2026)
Carneyism without Carney: Eh? Hey look at this: Delights to delectate. Object permanence: Replacing pharma patents with bounties; USTR v cheap leukemia meds; Plutocrats x wealth segregation; Anonymous Analytics; Scott Walker sells off donors;…
Q4 results highlights today: IREDA, Triveni Engg profit dips, Zara India revenue slips; Tilaknagar, Genesys, Univastu and Veranda Learning shine
Find all the latest Q4 results 2026 updates of Ahluwalia Contracts (India), Apex Frozen Foods, Archies, Balu Forge Industries, Brightcom Group, Bharat Gears, Confidence Petroleum India, Dhampur Bio Organics, Easy Trip Planners, Fiem Industries…
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Intech Investment Management LLC
Intech Investment Management LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 17.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm…
AbbVie (NYSE:ABBV) Raised to Strong-Buy at Wall Street Zen
AbbVie (NYSE:ABBV - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a 'buy' rating to a 'strong-buy' rating in a report issued on Saturday. Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or…
Savant Capital LLC Has $6.51 Million Stake in The Goldman Sachs Group, Inc. $GS
Savant Capital LLC trimmed its holdings in shares of The Goldman Sachs Group, Inc. (NYSE:GS - Free Report) by 16.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned…
microbes, glyphosate, fertilizer, famine and pillbugs
Some of you may recall this February post in which I wrote about how Bayer/Monsanto has been lobbying Trump, the US Supreme Court and Congress to gain liability exemption from injury and death lawsuits due to people becoming sick after exposure to…
A Letter From Prison About Faith, Truth, and Endurance
**Excerpted from the Epilogue, Movement I of The Blueprint of Life, shipping mid-June. For those unfamiliar with the Grenon family's persecution, I'll begin with a brief summary excerpted from my book, The War On Chlorine Dioxide. I will then share…
Receive a Daily briefing on Pharma Industry News
Get Started